JAK2 and breast neoplasm: Preclinically, it was observed by injection of MMTV-Wnt-1 tumor cells into mammary fat pads of mice that inhibition of EPO-induced JAK2 activation by Fedratinib was synergistic with chemotherapy for breast tumor-initiating cells [53].